Trial Profile
A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Indoximod (Primary) ; Sipuleucel-T (Primary)
- Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2018 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 01 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.